Updates are available Correction dated 2025-09-04
Click to view Correction: https://doi.org/10.3758/s13428-025-02818-9
-
Authors
Kaplan, Deanna M. https://orcid.org/0000-0002-9300-3029
Alvarez, Santiago J. Arconada
Palitsky, Roman
Choi, Hyoann
Clifford, Gari D.
Crozier, Melese
Dunlop, Boadie W.
Grant, George H.
Greenleaf, Morgan N.
Johnson, Leslie M.
Maples-Keller, Jessica
Levin-Aspenson, Holly F.
Mascaro, Jennifer S.
McDowall, Ariel
Pozzo, Nicole S.
Raison, Charles L.
Zarrabi, Ali John
Rothbaum, Barbara O.
Lam, Wilbur A.
-
Funding
Funding for this research was provided by:
National Institutes of Health (UL1TR002378)
- License Information
-
More Information
Article History
Accepted: 10 July 2025
First Online: 13 August 2025
Change Date: 4 September 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.3758/s13428-025-02818-9
Declarations
:
: The research reported in this article was reviewed and approved by the Emory University Institutional Review Board (IRB), STUDY00006765.
: All participants provided informed consent to be included in this research, as reviewed and approved by the Emory University IRB, STUDY00006765.
: Not applicable.
: DMK has served as a consultant for the Mind and Life Institute and the Oxford Research Encyclopedia of Global Public Health, and has received research support from the National Institutes of Health, the Georgia CTSA, the Tiny Blue Dot Foundation, the Sarlo Family Foundation, and the Vail Health Foundation. RP has received research support from the Tiny Blue Dot Foundation, the Jim Joseph Foundation via Shefa Jewish Psychedelic Support, and the Sarlo Family Foundation, and has consulted for the Harvard Divinity School Center for the Study of World Religions. CLR serves as a consultant for Usona Institute, Otsuka, and Novartis. JMK has received consulting payments from COMPASS Pathways and Ostuka and receives support from the Wounded Warrior Project (WWP) and Multidisciplinary Association of Psychedelic Studies. BWD has received research support from Boehringer Ingelheim, Beckley PsyTech, Compass Pathways, National Institute of Mental Health (NIMH), Reunion Neuroscience, and Usona Institute, and has served as a consultant for Biohaven, Myriad Neuroscience, and Otsuka. BOR has recently received funding from the Wounded Warrior Project, NIMH, National Science Foundation, and the Bob Woodruff Foundation. Additionally, BOR receives royalties from Oxford University Press, Guilford, American Psychiatric Publishing, Inc. (APPI), Psych Campus, and Emory University, and received advisory board payments from Jazz Pharmaceuticals, BioSerenity, Cerebral Therapeutics, Otsuka, Psychwire, and Senseye. BOR also owns equity in Virtually Better, Inc. that creates virtual environments. WAL is a co-founder and equity owner of Sanguina, Inc. and Cellia Science.
